Protection and repair of the injured spinal cord: a review of completed, ongoing, and planned clinical trials for acute spinal cord injury
- 1 November 2008
- journal article
- review article
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Neurosurgical Focus
- Vol. 25 (5) , E14
Abstract
Over the past 2 decades, advances in understanding the pathophysiology of spinal cord injury (SCI) have stimulated the recent emergence of several therapeutic strategies that are being examined in Phase I/II clinical trials. Ten randomized controlled trials examining methylprednisolone sodium succinate, tirilizad mesylate, monosialotetrahexosylganglioside, thyrotropin releasing hormone, gacyclidine, naloxone, and nimodipine have been completed. Although the primary outcomes in these trials were laregely negative, a secondary analysis of the North American Spinal Cord Injury Study II demonstrated that when administered within 8 hours of injury, methylprednisolone sodium succinate was associated with modest clinical benefits, which need to be weighed against potential complications. Thyrotropin releasing hormone (Phase II trial) and monosialotetrahexosylganglioside (Phase II and III trials) also showed some promise, but we are unaware of plans for future trials with these agents. These studies have, however, yielded many insights into the conduct of clinical trials for SCI. Several current or planned clinical trials are exploring interventions such as early surgical decompression (Surgical Treatment of Acute Spinal Cord Injury Study) and electrical field stimulation, neuroprotective strategies such as riluzole and minocycline, the inactivation of myelin inhibition by blocking Nogo and Rho, and the transplantation of various cellular substrates into the injured cord. Unfortunately, some experimental and poorly characterized SCI therapies are being offered outside a formal investigational structure, which will yield findings of limited scientific value and risk harm to patients with SCI who are understandably desperate for any intervention that might improve their function. Taken together, recent advances suggest that optimism for patients and clinicians alike is justified, as there is real hope that several safe and effective therapies for SCI may become available over the next decade.Keywords
This publication has 144 references indexed in Scilit:
- Prolonged hypothermia protects neonatal rat brain against hypoxic-ischemia by reducing both apoptosis and necrosisBrain and Development, 2005
- Defining the role of olfactory ensheathing cells in facilitating axon remyelination following damage to the spinal cordThe FASEB Journal, 2005
- Traumatic central cord syndrome: analysis of factors affecting the outcomeSurgical Neurology, 2005
- Minocycline Reduces Cell Death and Improves Functional Recovery after Traumatic Spinal Cord Injury in the RatJournal of Neurotrauma, 2003
- The effect of locomotor training combined with functional electrical stimulation in chronic spinal cord injured subjects: walking and reflex studiesBrain Research Reviews, 2002
- Improving axonal growth and functional recovery after experimental spinal cord injury by neutralizing myelin associated inhibitorsBrain Research Reviews, 2001
- The Catz-Itzkovich SCIM: a revised version of the Spinal Cord Independence MeasureDisability and Rehabilitation, 2001
- High-dose methylprednisolone may do more harm for spinal cord injuryMedical Hypotheses, 2000
- Effect of moderate hypothermia on lipid peroxidation in canine brain tissue after cardiac arrest and resuscitation.Stroke, 1994
- A Randomized, Controlled Trial of Methylprednisolone or Naloxone in the Treatment of Acute Spinal-Cord InjuryNew England Journal of Medicine, 1990